BBNX · Beta Bionics, Inc.

Track BBNX — free

$16.57 -0.02 (-0.12%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$745.48M

44.99M

Up next

Next earnings call

Nov 1, 2026 Est · unconfirmed · in 7 wks

Latest filing: 10-Q

filed Jul 29, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$119.01M

Trailing 12 months

Net income (TTM)

−$72.97M

Trailing 12 months

Revenue growth YoY

+37.8%

Year over year

Operating margin

-69.8%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-8.2%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$180.49M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+2.7%

Year over year · more shares

Price change (1Y)

-34.6%

Trailing year

Short interest

20.9%

Latest settlement · 9.0 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +0%

above

Price vs 50-day avg −4%

below

RSI (14) 40

neutral

MACD trend Negative

52-week position 33%

mid-range

Momentum

relative strength

Neutral

1-month return −8%

trailing

6-month return +55%

trailing

YTD return −46%

this year

Relative strength +37%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $17 › 200d $17 — 50d above 200d

Institutional flow Accumulating

+3% holders QoQ · +29 funds added

Insider flow Distributing

Net -$716.1K over 90 days · 100% sells

Short interest Rising

20.90% of float · ▲ +25.4% MoM · 9.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

136 holders — mid 1-yr range

Squeeze score 87

high risk · 0–100

Fundamentals

Strong

Revenue growth +54%

Y/Y

Gross margin 55%

expanding

EPS growth +79%

Y/Y

Free cash flow $-56.2M

Quant / Vol

risk profile

Very High

Volatility 81%

annualized · 1-yr

Max drawdown −72%

past year

ATR 7.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Jul 29, 2026

Estimated total revenue · full year 2026 Initiated $131M – $136M

prior FY $100.25M midpoint +33.2% Y/Y

Estimated new patient starts reimbursed through the PBP channel · full year 2026 Initiated 37% – 39%

Estimated gross margin · full year 2026 Initiated 58.5% – 59.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+0% Bullish

Price vs 50-day avg

−4% Neutral

RSI (14)

40 Neutral

MACD trend

Negative Bearish

52-week position

33% Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $17 › 200d $17 — 50d above 200d

Institutional flow Accumulating

+3% holders QoQ · +29 funds added

Insider flow Distributing

Net -$716.1K over 90 days · 100% sells

Short interest Rising

20.90% of float · ▲ +25.4% MoM · 9.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

136 holders — mid 1-yr range

Price context

position in its 52-week range

Range low $9 Now $17 · 33% Range high $32

vs 200-day avg +0% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
BBNX Beta Bionics, Inc. this stock	$745.48M	-45.6%	+53.9%	—	20.9%
ABT Abbott Laboratories	$177.58B	-18.6%	+5.7%	28.6	1.3%
MDT Medtronic plc	$116.35B	-5.3%	+8.4%	22.4	0.9%
SYK Stryker Corp	$105.70B	-21.6%	+11.2%	28.6	2.0%
BSX Boston Scientific Corp	$62.29B	-54.9%	+12.5%	17.4	3.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

136

% held: 106.9%
Net QoQ: -1.3M sh
Top holder: EVENTIDE ASSET MANAGEMENT…

Held Float

View

Held by Funds

Fund positions

121

View

Short & Settlement

Short Interest Rising

Shares short

9.4M

Days to cover: 9.0d
Change: +1.9M sh

View

Short Volume

Short vol %

47%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

37.7K

Value: $599.4K
As of: Aug 10, 2026

View

Off-Exchange

Off-exchange %

45.8%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$716.1K

Buyers / Sellers: 0 / 5

Buyers Sellers

View

Financials

Revenue (FY)

$100.3M

Net income (FY): $-73.2M
EPS diluted: $-1.81

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 29, 2026
This year: 11

View

Proposed Sales

Value

$779.1K

Shares: 40.3K
Filed: Sep 9, 2026

View

Exempt Offerings

Offering

$101.8M

Filed: Sep 15, 2023

View

Earnings & Events

Earnings Calls

Last call

Jul 29, 2026

View

Performance

	5D	20D	120D	MTD	YTD
BBNX	-16.8%	-8.4%	+54.9%	-16.9%	-45.6%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-15.7%	-6.6%	+37.0%	-16.6%	-57.7%

Key facts CIK 1674632 CUSIP 08659B102 13F (30d) 55 filings 55 filers Visit website Investor relations

BBNX · Beta Bionics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance